WST Gains 15.3% in Three Months as HVP Growth Strengthens Outlook

West Pharmaceutical Services, Inc. WST shares have gained 17.2% in the past three months, ahead of the Zacks Medical sector's 18.9% rise and the S&P 500's 2% advance. The move reflects improving operating momentum, but valuation leaves less room for execution misses.

The central question is whether High-Value Product demand, margin expansion and a higher 2026 outlook can support further gains after the recent run.

Image Source: Zacks Investment Research

WST's HVP Mix Supports the Rally

High-Value Product Components remain West's main growth engine. Second-quarter sales reached $424.1 million, up 19.4% year over year and 18.4% organically, representing 49% of total company sales.

Demand benefited from biologics, GLP-1 elastomers and customer upgrades to higher-quality containment solutions, including Annex 1-related conversions. NovaPure and FluroTec products were key contributors, while High-Value Product Delivery Devices sales increased 29.6% to $131.2 million.

Becton, Dickinson and Company BDX is investing $110 million to expand U.S. production of prefillable syringes for biologic and GLP-1 drug delivery. AptarGroup, Inc. ATR, another drug-delivery supplier, reported a 4% increase in Pharma sales in the second quarter, underscoring continued activity across injectable and advanced drug-delivery markets.

West's Q2 Beat Adds Fundamental Support

Second-quarter revenues increased 13.8% to $872.3 million, while organic sales grew 12.7%. Adjusted earnings of $2.37 per share rose 28.8% and beat the Zacks Consensus Estimate by 13.9%.

Proprietary Products revenues climbed 16.6% to $722.6 million. Gross margin expanded 200 basis points to 37.7%, and adjusted operating margin improved 230 basis points to 22.6%, showing the earnings benefit from richer product mix and operating leverage.

WST's Raised Outlook Extends the Growth Case

West raised its 2026 revenue outlook to $3.345 billion-$3.380 billion from $3.295 billion-$3.350 billion. Organic sales are now expected to increase 10%-11%, up from the prior 7%-9% range.

Adjusted earnings guidance rose to $8.85-$9.05 per share from $8.40-$8.75. Management now expects both GLP-1 and non-GLP-1 High-Value Product Components to grow in the high teens organically for the year, supporting continued mix improvement.

West's Premium Valuation Tests Further Upside

WST trades at 37.1X forward 12-month earnings, more than double the Zacks sub-industry's 17.8X multiple. The stock also trades above the Medical sector's 21.2X and the S&P 500's 20.7X.

The multiple is below WST's five-year median of 39.1X, but it still implies that investors are paying a sizable premium for growth and execution. Further appreciation may therefore require continued earnings delivery and sustained High-Value Product momentum.

Image Source: Zacks Investment Research

WST Risks Could Check the Momentum

Standard Products sales increased just 2.4% in the second quarter, while West Vantage revenues rose 2% and only 0.8% organically. West Vantage was also affected by cyber-related production downtime, which pushed some revenues into the second half.

Higher oil and commodity costs remain another pressure point. The July 1 sale of SmartDose 3.5mL also creates a portfolio transition, while the Dublin drug-handling ramp and other operational initiatives add execution risk.

Wrapping Up

WST's recent gain is supported by faster High-Value Product growth, wider margins and a stronger 2026 earnings outlook. Against that, the premium valuation and softer performance in Standard Products and West Vantage raise the threshold for additional upside.

Currently, West carries a Zacks Rank #3 (Hold). Likewise, Becton, Dickinson and Company, and AptarGroup also carry a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research